One of my colleagues performed experiments in vivo model for HER2-positive breast cancer cells.
[Cited from Supplementary Document (Materials and Methods)]
Cell transplantation. 231-Luc, HER2-60, or HER2-90 cells (2 × 105 cells in 30 µl of PBS) were injected as a single-cell suspension into the no. 4 mammary fat pad of 4-week-old female Balb/c nu/nu immune-deficient mice (Charles River, Burlington, MA, USA) that had been anesthetized by exposure to 1 to 3% isoflurane. Tumor volume was calculated as length × width2/2. For assay of tumor initiation, cells were injected into the no. 4 mammary fat pad of 4-week-old NOD/SCID mice (Charles River).
Mice anesthetized as described above were injected intraperitoneally with D-luciferin (20 mg/kg) at 10 to 20 min before whole-body imaging with an in vivo fluorescence imager (ClairvivoOPT; Shimadzu, Kyoto, Japan).
(Ref; Cancer Science Volume 105, Issue 7, pages 779–787, July 2014)
Hello, you may consider the Her2Sense probe from PerkinElmer:
The first pre-clinical imaging agent to be based on a commercialized therapeutic antibody.
Because Trastuzumab is well-characterized and validated, HER2Sense enables strong correlation between pre-clinical and clinical research.
Highly specific for the HER2/neu receptor and avoids systemic immune responses found in other antibody based imaging agents
HER2Sense also enables the interrogation of HER2/neu receptor-expressing non-breast cancer models, such as ovarian cancer, in living animals
http://www.perkinelmer.com/Catalog/Product/ID/NEV11060
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148106/
- Badges
- Science topic
- Similar topics
- Medicine
- Disease
- Disease Models
- Animal Models
- Rodent Models
- Mouse Models